Skip to main content

Julian Walfridsson group

Our knowledge of the genes and regulatory pathways that are involved in initiation, maintenance and development of acute myeloid leukemia (AML) remains incompletely understood. As a consequence, the development of more efficient treatments against AML has been limited and the prognosis remains unsatisfactory.

The main focus of our research is to discover factors and pathways that can serve as potential drug targets in AML and to delineate the underlying molecular mechanisms by which these effectors are involved in pathogenesis. With this objective we use functional genomic techniques, in vivo models, patient derived cells and cell- and molecular biology techniques.

Keywords: AML, RNAi screening, functional genomics, epigenetics, in vivo cancer models, molecular mechanisms

Members

Julian Walfridsson,Group Leader, Ph.D., Assistant Professor

Dr. Walfridsson was recruited to Karolinska Institutet as an assistant professor in 2011. He holds a Ph.D. degree in Cell and Molecular Biology at Karolinska Institutet, Sweden (2000) and did a postdoc at the Biotech Research Innovation Centre (BRIC), University of Copenhagen, Denmark (2007-2010).

Yaser Heshmati, Doctoral student

He was awarded a Master of Science in Human Genetics at the University of Social Welfare and Rehabilitation Sciences, Teheran, Iran, in 2010.

Phone: +46 (08) 585 83623

Aditya Harisankar, Doctoral student

He was awarded a Master of Science in Applied Biotechnology, at Uppsala University, Uppsala, in 2012.

Phone: +46 (08) 585 83623

Gözde Türköz, Doctoral student

She was awarded a Master of Science in Health Sciences, at Mersin University, Mersin, Turkey, in 2009.

Phone: +46 (08) 585 83623

Esmat Kamali Dolatabadi, PhD, Postdoc

She was awarded a PhD in Cellular and Molecular Biology at Teheran Islamic Azad University, Tehran, Iran, in 2013.

Phone: +46 (08) 585 83623

Projects

Acute myeloid leukemia (AML) is an aggressive blood cancer and less than 20% of adults and only about 60% of the children are cured of their disease, highlighting the urgent need of more effective treatment strategies.

Although the mechanisms of the disease remain incompletely understood, it is well established that cooperating genetic and epigenetic alterations contribute to AML pathogenesis. Various studies have demonstrated that individual AML tumor samples contain several hundreds to thousands of different gene mutations. The consequence of these genetic and epigenetic alterations is a widespread transcriptional deregulation of gene expression that give the cancer cells a proliferative growth advantage compared to normal cells. For the vast majority of these abnormalities it is not known which genes or downstream regulatory pathways that contribute to the initiation, maintenance and development of AML.

Current projects in our research group aims to identify and characterize novel biologically and clinically relevant genes with a role in AML pathogenesis and maintenance.

Specifically the projects aims to:

  1. Identify and characterize novel “druggable” epigenetic target genes that can serve as potential therapeutic targets to battle AML.
  2. Functionally annotate the causative mutations that are involved in AML pathogenesis.
  3. Determine the underlying molecular mechanisms by which the identified target genes contribute to AML pathogenesis and tumor expansion.

Towards these goals, we have established a cutting-edge technical and methodological platform, including flow cytometry, genome-wide mapping and analysis of epigenetic modifications (ChIP-sequencing and MeDIP-Seq), large-scale genetic screening systems, patient-derived AML cells and in vivo AML model systems.

The ultimate aim is that the proposed strategy can lead to the discovery of relevant drug targets that can facilitate the development of novel therapeutic interventions in AML treatment.

Financial support

  • Wallenberg Institute for Regenerative Medicine (WIRM)

  • Cancerfonden

  • Åke Wibergs Stiftelse

  • Magnus Bergvalls Stiftelse

  • Åke Olssons Stiftelse

Selected publications

24501218

21437270

20622008

20385584

20075857

19843847

17510629

17449867

17440621

15908586

12482946